百濟神州AH股均升超4% 將對Pharmacyclics發起的專利侵權指控開展堅決辯護
格隆匯6月16日丨百濟神州AH股均升超4%,分別報116.8港元和117.27元。百濟神州今日發佈公吿,Pharmacyclics LLC公司對百濟神州(BeiGene, Ltd. 和BeiGene USA, Inc.)提出申訴,聲稱百濟神州的百悦澤®(BRUKINSA®)侵犯了Pharmacyclics於2023年6月13日授權的一項專利。百濟神州的研發是原創性的,我們將對所有此類專利侵權指控開展堅決的辯護。


Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.